Familiar drugs may prevent cancer

Postgraduate Medical Journal

Volumn 77, Issue 910, 2001, Pages 492-497

  Sharma, R A ^a   Gescher, A J ^a   O'Byrne, K J ^a   Steward, W P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cancer chemoprevention; Cyclo oxygenase; Folate; Retinoids; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; ANTIESTROGEN; CAPTOPRIL; CELECOXIB; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FOLIC ACID; HERBACEOUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; RETINOID; TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HOT FLUSH; HUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM; VAGINA BLEEDING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICARCINOGENIC AGENTS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; FEMALE; FOLIC ACID; HUMANS; MALE; NEOPLASMS; PYRAZOLES; RALOXIFENE; SULFONAMIDES; TAMOXIFEN; VITAMIN A;

EID: 0034888452     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.910.492     Document Type: Review

References (60)

1. Recent advances: Oncology
2. Tamoxifen: A personal retrospective
3. Chemoprevention of cancer with retinoids
4. Colorectal cancer chemoprevention: Biochemical targets and clinical development of promising agents
5. A new anti-oestrogenic agent in late breast cancer
6. Tamoxifen and contralateral breast cancer
7. Etiology of cancer: Hormonal factors
8. Endogenous hormones as a major factor in human cancer
9. Chemoprevention of cancer
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
12. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
13. Tamoxifen for early breast cancer: An overview of the randomised trials
14. The effect of raloxifene on risk of breast cancer in postmenopausal women
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
16. Prevention of breast cancer with tamoxifen
17. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention
18. Effect of anti-inflammatory drugs on overall risk of common cancer: A case-control study in a general practice research database
19. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
20. Aspirin use and reduced risk of fatal colon cancer
21. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing
22. The evolution of cancer of the colon and rectum
23. Polyps and cancer of the large bowel: A necropsy study in Liverpool
24. Biology of the adenomatous polyposis coli tumor suppressor
25. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
26. Cyclooxygenase-2 and carcinogenesis
27. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
28. Are rofecoxib and celecoxib safer NSAIDs?
29. The gastrointestinal toxicity of aspirin - An overview of randomised controlled trials
30. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs: A pooled analysis of published studies and a new population-based study
31. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose
32. Aspirin and the potential role of prostaglandins in colon cancer
33. Selected micronutrient intake and the risk of colorectal cancer
34. Colorectal cancer: Molecules and populations
35. Hypomethylation of ras oncogenes in primary human cancers
36. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer
37. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma
38. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study
39. Retinoids in chemoprevention and differentiation therapy
40. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia
41. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomised double-blind controlled trial
42. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
43. Adjuvant treatment of stage I lung cancer with high-dose vitamin A
44. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer
45. Do inhibitors of angiotensin-I-converting enzyme protect against the risk of cancer?
46. Clinical applications of research on angiogenesis
47. The mechanisms of cancer mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
48. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
49. Cancer chemoprevention by dietary constituents: A salutary tale of failure and promise
50. Phase I chemoprevention clinical trial of curcumin
51. Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex
52. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
53. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
54. Curcumin is an in vivo inhibitor of angiogenesis
55. Strategy and planning for chemopreventive drug development: Clinical development plans II
56. Blocking and suppressing mechanisms of chemoprevention by dietary constituents
57. A genetic model for colorectal tumorigenesis
58. Immunoprevention of cancer: Is the time ripe?
59. Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention
60. Cancer chemoprevention: A clinical reality